78results about How to "Good release performance" patented technology

A system and method for managing a permit-based parking environment governed by a parking program. The permit-based parking environment includes a number of parking permits each including a unique RFID tag and tag number. One or more RFID readers are used to scan the vehicles parked in the parking environment to determine if a RFID tag is associated with the parked vehicle. The results of the scan along with information related to the parked vehicle are provided to a permit management system to determine if the vehicle is parked within the scope of privileges pre-defined for that vehicle, pursuant to the parking program governing the parking environment. The permit management system stores, manages, and monitors data related to the permits controlled under the parking program.

Disclosed is a percutaneous absorption preparation which enables the stable administration of an antidementia drug over a long period of time. More particularly, the percutaneous absorption preparation of the antidementia drug which is used as a plaster on skin comprises at least an adherent layer, an intermediate membrane, and a drug reservoir layer sequentially from the side which is plastered on skin, wherein the drug reservoir layer comprises at least an antidementia drug, an aminated polymer, a polyhydric alcohol, and one or more carboxylic acid esters, the intermediate membrane enables the controlled permeation of the antidementia drug into the side of skin, the adherent layer enables the plastering of the percutaneous absorption preparation on skin, and is permeable to the antidementia drug.

The invention belongs to the field of release materials and discloses a light release force solvent-free organic silicon release agent as well as a preparation method and application. The light release force solvent-free organic silicon release agent disclosed by the invention comprises the following components in parts by mass: 100 parts of vinyl polysiloxane, 2-20 parts of hydrogen-containing polysiloxane, 2-10 parts of an anchoring agent, 2-10 parts of a fluorine-containing release force adjusting agent and 2-10 parts of a platinum catalyst, wherein the functional group ratio of vinyl polysiloxane to hydrogen-containing polysiloxane is H/Vi=1.0-5.0. The release agent disclosed by the invention is applied to release paper. The release paper prepared from the release agent has super lightrelease force, the normal-temperature release force of the release paper is as low as 1.3g/25mm, the aging release force of the release paper is as low as 1.7g/25mm, the release paper is stable in release property and can be applied to practical production processing, and the requirements of electronic processing industries on super light release force in application scenes are met.

An electrostatic image developing toner is disclosed, comprising toner particles composed of a core containing resin and a colorant and a shell containing a resin, wherein the standard deviation of shape factor SF-1 of the toner particles and the standard deviation of shape factor SF-2 fall within the specific range, and the ratio of maximum thickness of the shell to minimum thickness falls within the specific range.

The invention discloses an ultraviolet light cured non-silicon release agent, which is composed of the following components in parts by weight: 50 to 80 parts of vinyl ether functionalized acrylic resin, 10 to 30 parts of dodecyl vinyl ether, 10 to 20 parts of triethyleneglycol divinyl ether, and 1 to 3 parts of photoinitiator. The preparation method comprises the following steps: step one, synthesizing vinyl ether functionalized acrylic resin; step two, adding 10 to 30 parts of dodecyl vinyl ether and 10 to 20 parts of triethyleneglycol divinyl ether into the 50-80 parts of vinyl ether functionalized acrylic prepolymer; step three, stirring and evenly mixing, then adding 1 to 3 parts of photoinitiator, stirring and evenly mixing so as to obtain ultraviolet light cured non-silicon release agent; step four, painting the obtained ultraviolet light cured non-silicon release agent on a film, and carrying out radiation curing by placing the film under an ultraviolet lamp. The invention aims to provide a non-mobility solvent-free ultraviolet light cured non-silicon release agent with a stable releasing performance and a preparation method thereof.

The invention discloses a mineral processing and metallurgical technology which comprehensively uses multi-metallic ore through a chloride carrier chlorination process, which comprises calcining crude ore into slag through grinding, flotation and concentrate powder, separating out gold, silver liquid and barren liquor from slag through pitch absorption by penetrating through chloridization leach pregnant solution, preparing gold and silver through chemically separating pregnant solution, depositing and filtering barren liquor to recycle and separate copper, lead and zinc, and reusing filter solution which is sodium chloride passing through the steps of chlorination leaching above. The mineral processing and metallurgical technology of the invention has the characteristics of no toxic and environment-friendly, fast speed, low cost and multiple-kind comprehensive recycling products. The invention has high comprehensive recovering index, the recovery ratio of gold and silver all can be larger than 95%, the recovery ratio copper, lead and zinc and the like which are comprehensively recovered all can be larger than 90%, and the invention can change ferro-sulphur ore into iron-smelting raw material. The invention is superior to traditional, which has significant technology superiority, economic benefits superiority, environmental benefit superiority and high comprehensive utilization degree.

The invention belongs to the technical field of release materials, and discloses a solvent-free normal-temperature fast-curing silicone release agent and a preparation method thereof. The solvent-freenormal-temperature fast-curing silicone release agent provided by the invention comprises the following components in parts by mass: 100 parts of vinyl silicone oil, 3-10 parts of hydrogen-containingsilicone oil, 1-5 parts of an inhibitor and 1-3 parts of a catalyst. During the application of the release agent, various components of the release agent provided by the invention are mixed and stirred uniformly, and then the obtained mixture is coated on a substrate, wherein quick curing can be realized at 60 DEG C, and the curing time is 10s-2min. According to the difference of the usage amounts of the components and the varieties of the inhibitor in the release agent, the curing temperature can be adjusted (60-200 DEG C), and the curing time can also be adjusted. Moreover, the release paper sample obtained by using the release agent provided by the invention has stable release performance.

The invention relates to a choline fenofibrate film-controlled enteric slow-release pellet capsule. A slow-release film of the choline fenofibrate film-controlled enteric slow-release pellet utilizes Eurdragit RS 30D as a film-formation material. A pellet core of the choline fenofibrate film-controlled enteric slow-release pellet contains low-substituted hydroxypropyl cellulose having high expansibility, and also contains a pharmaceutically acceptable common excipient for the slow-release pellet, wherein preferably, the excipient comprises microcrystalline cellulose, and the pellet core comprises 10 to 40wt% of the low-substituted hydroxypropyl cellulose. The slow-release film comprises Eurdragit RS 30D, triethyl citrate as a plasticizer and talcum powder as an antiplastering aid, wherein preferably, a ratio of urdragit RS 30D to triethyl citrate to talcum powder is 30: 3: 4 and a film weight increasing ratio is in a range of 20 to 38%. The choline fenofibrate film-controlled enteric slow-release pellet comprises the pellet core containing low-substituted hydroxypropyl cellulose having high water expansibility and thus after absorbing water, the choline fenofibrate film-controlled enteric slow-release pellet expands so that the slow-release film is stretched; the thickness of the slow-release film is reduced; the water-permeable micropore size is increased; and permeability is improved and the permeability reduction caused by film aging is counteracted. Therefore, in middle and later stages, the choline fenofibrate film-controlled enteric slow-release pellet release rate is basically constant; in the last stage, residues are less; and stable release performances can be kept in the period of validity.

The invention relates to the technical field of thermal transfer printing lettering film, and in particular, relates to a high-elasticity silicone rubber lettering film and a preparation method and anapplication method thereof. The high-elasticity silicone rubber lettering film comprises a load-bearing substrate, a release layer, a surface layer silicone rubber ink layer, an anti-photopermeable silicone rubber ink layer, an adhesive interfacial agent layer and a TPU hot melt adhesive film which are connected from bottom to top successively; the adhesive interfacial agent layer is prepared from an adhesive interfacial agent, and the adhesive interfacial agent is an adhesive interfacial agent containing dual-resin components. The silicone rubber lettering film has the advantages of both thesilicone rubber material and the TPU material, has good elasticity, tearing strength, weatherability, yellowing resistance, water washing resistance and other comprehensive properties, has layers noteasy to separate, is not easy to discolor or fade by sunlight exposure, and has the water-washing fading rate not less than 0.5%, is not easy to dye when being mixed and washed with materials with other colors, and is high in stability, easy to bond with a variety of materials, high in bonding strength, not easy to peel off, good in stability, delicate in hand feeling, good in aesthetic degree, and long in service life.

The invention relates to a venlafaxine hydrochloride film-controlled slow-release pellet capsule. A slow-release film of the venlafaxine hydrochloride film-controlled slow-release pellet utilizes Kollicoat SR30D as a film-formation material. A pellet core of the venlafaxine hydrochloride film-controlled slow-release pellet contains low-substituted hydroxyprepyl cellulose having high expansibility, and also contains a pharmaceutically-acceptable common excipient for the slow-release pellet, wherein preferably, the excipient comprises microcrystalline cellulose, and the pellet core comprises 10 to 40wt% of low-substituted hydroxyprepyl cellulose. The slow-release film comprises Kollicoat SR30D, triethyl citrate as a plasticizer and talcum powder as an antiplastering aid, wherein preferably, a ratio of Kollicoat SR30D to triethyl citrate to talcum powder is 30: 1: 4 and a film weight increasing ratio is in a range of 21 to 39%. The venlafaxine hydrochloride film-controlled slow-release pellet comprises the pellet core containing low-substituted hydroxyprepyl cellulose having high water expansibility and thus after absorbing water, the venlafaxine hydrochloride film-controlled slow-release pellet obviously expands so that the slow-release film is stretched; the thickness of the slow-release film is reduced; the water-permeable micropore size is increased; and permeability is improved and the permeability reduction caused by film aging is counteracted. Therefore, in middle and later stages, the venlafaxine hydrochloride film-controlled slow-release pellet release rate is basically constant; in the last stage, residues are less; and stable release performances can be kept in the period of validity.

The invention relates to a glipizide film-controlled slow-release pellet capsule. A slow-release film of the glipizide film-controlled slow-release pellet utilizes Eurdragit RL 30D as a film-formation material. A pellet core of the glipizide film-controlled slow-release pellet contains sodium carboxymethyl starch having high expansibility, and also contains pharmaceutically-acceptable common excipients for the slow-release pellet, wherein preferably, the excipients comprise microcrystalline cellulose, lactose and sodium dodecyl sulfate, and the pellet core comprises 5 to 20wt% of sodium carboxymethyl starch. The slow-release film comprises Eurdragit RL 30D, triethyl citrate as a plasticizer and talcum powder as an antiplastering aid, wherein preferably, a ratio of Eurdragit RL 30D to triethyl citrate to talcum powder is 30: 3: 4 and a film weight increasing ratio is in a range of 17 to 36%. The glipizide film-controlled slow-release pellet comprises the pellet core containing sodium carboxymethyl starch having high water expansibility and thus after absorbing water, the glipizide film-controlled slow-release pellet obviously expands so that the slow-release film is stretched; the thickness of the slow-release film is reduced; the water-permeable micropore size is increased; and permeability is improved and the permeability reduction caused by film aging is counteracted. Therefore, in middle and later stages, the glipizide film-controlled slow-release pellet release rate is basically constant; in the last stage, residues are less; and stable release performances can be kept in the period of validity.

The invention relates to the field of medicines, and particularly relates to a liraglutide multivesicular liposome and a preparation method and an application thereof. The liraglutide multivesicular liposome provided by the invention comprises liraglutide, a membrane material, an osmotic pressure regulator and a stabilizer. The liraglutide multivesicular liposome prepared by the invention has goodstability, high drug encapsulation rate, large drug loading capacity, slow and steady drug release rate and no burst release phenomenon, significantly improves the bioavailability of the drug, thereby improving the curative effect, reduces dose-related side effects of the drug and medication cost and has a higher application value. Experiments shows that the liposome provided by the present invention can continuously release the drug in vitro for about 432 hours, and provide a stable blood concentration in vivo, significantly prolongs in-vivo retention time compared to other injections, showsobvious pharmacokinetic characteristics of a sustained release preparation, can provide a normal steady blood glucose level, plays hypoglycemic effect for 312 hours, and has the relative bioavailability of 661% to injections.

The invention relates to the technical field of ironmaking agents, in particular to a mold release agent. The mold release agent is prepared by mixing and stirring a dry material and water, the dry material comprises, by weight, 0.5-1.5% of carboxymethylcellulose, 10.0-15% of sodium bentonite, 50-60% of low carbon coal slurry, 15-20% of aluminum-magnesium refractory mortar, 10-15% of coal powder and the balance water, wherein the weight of the water is 9-11 times of the total weight of the dry material. The preparation method comprises the steps that when being poured, the mold release agent forms a sintered layer of 1-2 mm under the high temperature of molten iron, an isolation layer can be effectively formed between the molten iron and a cast iron mold, a cast iron block can smoothly fall off from the cast iron mold, the mold release performance of the mold release agent is good, the mold release rate is up to 100%, the cast iron mold can be protected and is not easily deformed, theservice life of the cast iron mold can be remarkably prolonged, the low carbon coal slurry is generally thrown away as waste, the low carbon coal slurry is used as the main component of the mold release agent, and waste using is achieved, so that the cost of the release agent is low, and popularization is facilitated.

A motor-vehicle armrest has a base fixed on the vehicle and defining an axis and an armrest part pivotal on the base about the axis and having a first concave surface turned radially inward toward a second convex surface of the base. A wedge-shaped sprag is slidable between the surfaces generally angularly of the axis between a locking position in which the armrest part is arrested relative to the base and a release position in which pivoting of the armrest part with respect to the base is possible. The sprag has a first contact face cooperating with the first surface of the armrest part and a second nonparallel contact face cooperating with the second surface of the base. The sprag is biased into the locking position and can be moved into the release position.

The invention provides a microcapsule preparation for optimizing embedding. The microcapsule preparation adopts a wall material and wall material assistant mixture as a release material, the wall material assistant comprises fatty acid-based C12-22 saturated or unsaturated fatty acid glyceride, and the fatty acid glyceride is fatty acid monoglyceride or fatty acid diglyceride or a mixture containing fatty acid monoglyceride and fatty acid diglyceride according to an arbitrary ratio. The microcapsule preparation using the fatty acid glyceride has an excellent embedding promotion effect, can effectively reduce the surface core material content, and optimizes the active substance release behavior.

The invention relates to a cefaclor film-controlled slow-release pellet capsule. A slow-release film of the cefaclor film-controlled slow-release pellet utilizes a mixture of aqueous dispersion Eurdragit RL 30D and Eurdragit RS 30D as a film-formation material, wherein a weight ratio of Eurdragit RL 30D to Eurdragit RS 30D in the mixture is 4: 1. A pellet core of the cefaclor film-controlled slow-release pellet contains sodium carboxymethyl starch having high expansibility, and also contains pharmaceutically-acceptable common excipients for the slow-release pellet, wherein preferably, the excipients comprise microcrystalline cellulose and lactose, and the pellet core comprises 5 to 20wt% of the sodium carboxymethyl starch. The slow-release film comprises the mixture of Eurdragit RL 30D and Eurdragit RS 30D, triethyl citrate as a plasticizer, and talcum powder as an antiplastering aid, wherein preferably, a ratio of Eurdragit RL 30D to Eurdragit RS 30D to triethyl citrate to talcum powder is 24: 6: 2: 4 and a film weight increasing ratio is in a range of 23 to 40%. The cefaclor film-controlled slow-release pellet comprises the pellet core containing sodium carboxymethyl starch having high water expansibility and thus after absorbing water, the cefaclor film-controlled slow-release pellet obviously expands so that the slow-release film is stretched; the thickness of the slow-release film is reduced; the water-permeable micropore size is increased; and permeability is improved and the permeability reduction caused by film aging is counteracted. Therefore, in middle and later stages, the cefaclor film-controlled slow-release pellet release rate is basically constant; in the last stage, residues are less; and stable release performances can be kept in the period of validity.

The invention relates to a metoprolol fumarate film-controlled slow-release pellet capsule. A slow-release film of the metoprolol fumarate film-controlled slow-release pellet utilizes Eurdragit RS 30D as a film-formation material. A pellet core of the metoprolol fumarate film-controlled slow-release pellet contains croscarmellose sodium having high expansibility, and also contains a pharmaceutically-acceptable common excipient for the slow-release pellet, wherein preferably, the excipient comprises microcrystalline cellulose, and the pellet core comprises 5 to 20wt% of croscarmellose sodium. The slow-release film comprises Eurdragit RS 30D, triethyl citrate as a plasticizer, and talcum powder as an antiplastering aid, wherein preferably, a ratio of Eurdragit RS 30D to triethyl citrate to talcum powder is 30: 3: 4 and a film weight increasing ratio is in a range of 18 to 33%. The metoprolol fumarate film-controlled slow-release pellet comprises the pellet core containing croscarmellose sodium having high water expansibility and thus after absorbing water, the metoprolol fumarate film-controlled slow-release pellet obviously expands so that the slow-release film is stretched; the thickness of the slow-release film is reduced; the water-permeable micropore size is increased; and permeability is improved and the permeability reduction caused by film aging is counteracted. Therefore, in middle and later stages, the metoprolol fumarate film-controlled slow-release pellet release rate is basically constant; in the last stage, residues are less; and stable release performances can be kept in the period of validity.

The invention relates to a preparation method of a primary-taste modified rice fresh keeping agent material, and belongs to the technical field of food additive materials. The technical scheme adoptedby the invention lies in that the primary-taste modified rice fresh keeping agent material is prepared by using rice husks as raw materials; the rice husks contain rich antioxidation peptide, the rice husks are subjected to enzymolysis and collection, the rice husks are coated with essential oil, and a microcapsule structure is formed; the microcapsule structure can effectively relieve the releasing efficiency of the essential oil, so that the essential oil material has excellent slow release performance; in the storage course, due to massive release of the essential oil at the initial stage,after the essential oil disappears at the later stage, due to the effects of the antioxidation peptide, the fresh keeping agent material continues forming antioxygenic properties, so that the antioxidation durability of the rice fresh keeping agent material can be effectively improved; an adsorbent material is prepared by using the rice husks as raw materials, so that when the adsorbent materialis added to fresh keeping agent microspheres, the adsorbent material can effectively adsorb surplus essential oil smell; and besides, excellent pore canal structure of the fresh keeping agent materialcan be maintained, and the releasing properties and the durability of the fresh keeping agent material can be stable.